Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia

The PI3Kδ isoform (PIK3CD), also known as P110δ, is predominately expressed in leukocytes and has been implicated as a potential target in the treatment of hematological malignancies. In this report, we detailed the pharmacologic properties of puquitinib, a novel, orally available PI3Kδ inhibitor. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chengying, He, Ye, Zhen, Mingyue, Wang, Yulan, Xu, Yongping, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497803/
https://www.ncbi.nlm.nih.gov/pubmed/28418085
http://dx.doi.org/10.1111/cas.13263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497803/
https://www.ncbi.nlm.nih.gov/pubmed/28418085
http://dx.doi.org/10.1111/cas.13263

Ejemplares similares